$0.14 EPS Expected for Exelixis, Inc. (EXEL)

July 27, 2018 - By Catherine Diaz

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment decreased to 1.16 in Q1 2018. Its down 0.41, from 1.57 in 2017Q4. It is negative, as 39 investors sold Exelixis, Inc. shares while 74 reduced holdings. 47 funds opened positions while 84 raised stakes. 225.93 million shares or 2.97% less from 232.85 million shares in 2017Q4 were reported.
Dimensional Fund Advsrs L P holds 1.04 million shares. Ubs Asset Mngmt Americas holds 0% or 1.37M shares in its portfolio. State Street Corporation has invested 0.01% in Exelixis, Inc. (NASDAQ:EXEL). Amalgamated Savings Bank has 0.04% invested in Exelixis, Inc. (NASDAQ:EXEL) for 62,473 shares. Strs Ohio holds 235,000 shares. Cutler Mngmt Ltd Company accumulated 10,000 shares. Amundi Pioneer Asset accumulated 14,900 shares or 0% of the stock. Rock Springs Cap Management Limited Partnership invested 0.17% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Raymond James And Assoc owns 48,601 shares. Earnest Prtn Lc reported 0% in Exelixis, Inc. (NASDAQ:EXEL). Stratos Wealth Ptnrs has 0% invested in Exelixis, Inc. (NASDAQ:EXEL). Federated Invsts Pa holds 144,212 shares. Hbk Investments Lp reported 0.05% stake. Teacher Retirement Systems Of Texas has 65,591 shares. Fincl Bank Of Montreal Can owns 870,106 shares.

Since February 28, 2018, it had 0 buys, and 25 sales for $18.35 million activity. Hessekiel Jeffrey also sold $1.35M worth of Exelixis, Inc. (NASDAQ:EXEL) shares. On Friday, June 1 Schwab Gisela sold $468,000 worth of Exelixis, Inc. (NASDAQ:EXEL) or 22,500 shares. Another trade for 90,000 shares valued at $1.85M was sold by MORRISSEY MICHAEL. $302,920 worth of Exelixis, Inc. (NASDAQ:EXEL) shares were sold by WYSZOMIERSKI JACK L. On Wednesday, May 9 the insider COHEN CHARLES sold $321,300. The insider PAPADOPOULOS STELIOS sold $360,750.

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.14 EPS on August, 1 after the close.They anticipate $0.06 EPS change or 75.00 % from last quarter’s $0.08 EPS. EXEL’s profit would be $41.56M giving it 38.73 P/E if the $0.14 EPS is correct. After having $0.37 EPS previously, Exelixis, Inc.’s analysts see -62.16 % EPS growth. The stock increased 3.04% or $0.64 during the last trading session, reaching $21.69. About 3.67M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has risen 6.49% since July 27, 2017 and is uptrending. It has underperformed by 6.08% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 3 analysts covering Exelixis (NASDAQ:EXEL), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Exelixis has $36.0 highest and $29 lowest target. $32.50’s average target is 49.84% above currents $21.69 stock price. Exelixis had 4 analyst reports since February 27, 2018 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Tuesday, February 27 report. As per Thursday, May 3, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, February 27 report. The company was upgraded on Tuesday, February 27 by Oppenheimer.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $6.44 billion. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 26.81 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

More news for Exelixis, Inc. (NASDAQ:EXEL) were recently published by: Seekingalpha.com, which released: “Results from late-stage study of Exelixis’ Cabometyx in liver cancer published in NEJM” on July 05, 2018. Fool.com‘s article titled: “Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc.” and published on July 25, 2018 is yet another important article.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.